Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. (Nasdaq: ESLA) is a clinical-stage biopharmaceutical company focused on developing immunotherapy treatments for cancer and inflammatory diseases. The company became publicly traded through a SPAC merger and operates in the biotechnology and immunology sector. On September 8, 2026, Estrella filed an 8-K current report with the Securities and Exchange Commission under accession number 0001213900-26-098123, signaling a reportable corporate event. As a post-merger public company, ESLA continues to advance its pipeline of immune-modulating therapies. Investors and researchers seeking comprehensive filing history, merger documents, and real-time event coverage for ESLA can access the full dataset by signing up at SpacDesk.